Although PD-1 inhibitors demonstrated promising clinical results for HCC in Phase 1/2 studies with the response rates ranging from 15% to 20%, improved overall survival was not found in Phase 3 studies [147,148,149,150]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.